Clay Siegall Entrepreneur and Co-founder of Seattle Genetics
The headquarters of Seattle Genetics is located at Bothell Cascade Business Park and the building while deceiving on the outside the inside is different. In the lobby of Building Three has a unique green sculpture made with Lego bricks. The sculpture is a triangular shape that is a model of a simplified human antibody. This is fitting for the Seattle Genetics company that has focused on human antibodies study, manipulating and using it to create cancer drugs. Their drug is named Adcetris and created for the use of treating Hodgkin Lymphoma, which is a cancer of the lymph glands but can spread to other organs.
These cancer drug antibodies therapies deliver a toxic compound into cancer cells to destroy them from the inside. The Seattle Genetics company that has a market value of almost $10 billion is the largest biotech company in Washington with 900 employees. The increased growth the company expects to hire 200 more employees this year. Since extensive testing has been done on Adcetris with positive results and sales are expected to soar.
The CEO, president, cofounder, and chairman, Clay Siegall has said the company is an up-and-coming global oncology company. Mr. Siegall has taken the company from when it sold international commercial rights to Takeda Oncology to research on Adcetris and then partnering with Takeda again. This partnership and Seattle Genetics recently opened an office in Switzerland. The company now 18 years in business has seen over the past five years their stock prices triple.
Currently, Seattle Genetics has eleven drugs being researched and tested with four that have the potential for high sales demands. Adcetris has been approved by the Food and Drug Administration (FDA) and is one of the few drugs on the market to treat Hodgkin Lymphoma.
Seattle Genetics co-founder Clay Siegall founded the company in 1998 and prior held a position at Bristol-Myers Squibb Pharmaceutical Research Institute. Before that position, Mr. Siegall held a position at the National Cancer Institute.
Mr. Siegall attended George Washington University where he earned a Ph.D. in Genetics. He also attended the University of Maryland where he earned a B.S. in Zoology. He is the author of more than 70 publications. Clay Siegall sits on the Board of Directors of Alder BioPharmacuticals, which is a private biotechnology company. He also sits on the Board of Directors at Ultragenyx Pharmaceutical Inc. a biopharmaceutical company that is focused on the development of products for rare and extremely rare diseases.